Showing Results for: “Covid-19”

Navigate the challenges of the COVID-19 pandemic for students with diabetes. Access resources, legal rights, and support for a safe school environment.

Expanded results from the first-of-its-kind clinical trial explores the use of SGLT2 inhibitor for COVID-19 patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19. Additional findings from the trial were presented today at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with cardiometabolic risk factors, including

Study shows diabetes patients not taking medication experienced longer hospitalization and recovery with greatest toll among Latinx populations A new study reveals unmanaged diabetes is a key factor in COVID-19 severity and complications, particularly among Hispanic and Latinx populations. Findings of the retrospective study were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Forty percent of Americans who have died of COVID-19 have had diabetes, and 1 in 10 people with diabetes hospitalized for COVID-19 die within one week – making diabetes a

“With more than 40 percent of all COVID-19 related deaths occurring among people with diabetes, many if not all adults with the disease, should strongly consider getting vaccine boosters. We urge people with diabetes to consult with their health care providers to discuss if the booster is appropriate for them,” said Dr. Robert Gabbay, Chief Scientific and Medical Officer for the American Diabetes Association. # # # , About the American Diabetes Association Every day more than 4,000 people are newly diagnosed with diabetes in America. More than 122 million Americans have diabetes or prediabetes